annual cash & cash equivalents:
$298.26M-$91.22M(-23.42%)Summary
- As of today (June 29, 2025), CRSP annual cash & cash equivalents is $298.26 million, with the most recent change of -$91.22 million (-23.42%) on December 31, 2024.
- During the last 3 years, CRSP annual cash & cash equivalents has fallen by -$624.77 million (-67.69%).
- CRSP annual cash & cash equivalents is now -74.48% below its all-time high of $1.17 billion, reached on December 31, 2020.
Performance
CRSP Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$235.18M-$63.07M(-21.15%)Summary
- As of today (June 29, 2025), CRSP quarterly cash & cash equivalents is $235.18 million, with the most recent change of -$63.07 million (-21.15%) on March 31, 2025.
- Over the past year, CRSP quarterly cash & cash equivalents has dropped by -$472.24 million (-66.76%).
- CRSP quarterly cash & cash equivalents is now -85.72% below its all-time high of $1.65 billion, reached on June 30, 2021.
Performance
CRSP quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
CRSP Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -23.4% | -66.8% |
| 3 y3 years | -67.7% | -65.6% |
| 5 y5 years | -68.4% | -73.6% |
CRSP Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -67.7% | +40.8% | -66.8% | +11.0% |
| 5 y | 5-year | -74.5% | +40.8% | -85.7% | +11.0% |
| alltime | all time | -74.5% | >+9999.0% | -85.7% | +50.8% |
CRSP Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $235.18M(-21.1%) |
| Dec 2024 | $298.26M(-23.4%) | $298.26M(+32.2%) |
| Sep 2024 | - | $225.67M(-53.4%) |
| Jun 2024 | - | $484.47M(-31.5%) |
| Mar 2024 | - | $707.43M(+81.6%) |
| Dec 2023 | $389.48M(+83.8%) | $389.48M(-26.2%) |
| Sep 2023 | - | $527.76M(+18.7%) |
| Jun 2023 | - | $444.80M(+29.1%) |
| Mar 2023 | - | $344.41M(+62.5%) |
| Dec 2022 | $211.88M(-77.0%) | $211.88M(-57.1%) |
| Sep 2022 | - | $494.15M(-0.6%) |
| Jun 2022 | - | $496.89M(-27.3%) |
| Mar 2022 | - | $683.91M(-25.9%) |
| Dec 2021 | $923.03M(-21.0%) | $923.03M(-8.8%) |
| Sep 2021 | - | $1.01B(-38.6%) |
| Jun 2021 | - | $1.65B(+46.2%) |
| Mar 2021 | - | $1.13B(-3.6%) |
| Dec 2020 | $1.17B | $1.17B(+12.2%) |
| Sep 2020 | - | $1.04B(+10.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $945.07M(+6.2%) |
| Mar 2020 | - | $889.71M(-5.7%) |
| Dec 2019 | $943.77M(+106.7%) | $943.77M(+49.9%) |
| Sep 2019 | - | $629.72M(+47.2%) |
| Jun 2019 | - | $427.88M(-2.2%) |
| Mar 2019 | - | $437.55M(-4.2%) |
| Dec 2018 | $456.65M(+90.5%) | $456.65M(-6.3%) |
| Sep 2018 | - | $487.30M(+52.4%) |
| Jun 2018 | - | $319.74M(-6.4%) |
| Mar 2018 | - | $341.77M(+42.5%) |
| Dec 2017 | $239.76M(-24.0%) | $239.76M(-5.4%) |
| Sep 2017 | - | $253.52M(-6.9%) |
| Jun 2017 | - | $272.26M(-5.7%) |
| Mar 2017 | - | $288.87M(-8.4%) |
| Dec 2016 | $315.52M(+102.3%) | $315.52M(+38.0%) |
| Sep 2016 | - | $228.61M(-7.4%) |
| Jun 2016 | - | $246.85M(+58.3%) |
| Dec 2015 | $155.96M(>+9900.0%) | $155.96M |
| Dec 2014 | $945.00K | - |
FAQ
- What is CRISPR Therapeutics AG annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual cash & cash equivalents year-on-year change?
- What is CRISPR Therapeutics AG quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly cash & cash equivalents year-on-year change?
What is CRISPR Therapeutics AG annual cash & cash equivalents?
The current annual cash & cash equivalents of CRSP is $298.26M
What is the all time high annual cash & cash equivalents for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual cash & cash equivalents is $1.17B
What is CRISPR Therapeutics AG annual cash & cash equivalents year-on-year change?
Over the past year, CRSP annual cash & cash equivalents has changed by -$91.22M (-23.42%)
What is CRISPR Therapeutics AG quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of CRSP is $235.18M
What is the all time high quarterly cash & cash equivalents for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly cash & cash equivalents is $1.65B
What is CRISPR Therapeutics AG quarterly cash & cash equivalents year-on-year change?
Over the past year, CRSP quarterly cash & cash equivalents has changed by -$472.24M (-66.76%)